
REFERENCES

1. Amstalden M., Zieba DA, Garcia MR, R. L. Stanko T. H. Welsh Jr., Hansel WH., and Williams G.L., “Evidence that lamprey GnRH-III does not release FSH selectively in cattle”. *Reproduction* 127: 25-42, 2004.
2. Anderson L., “Intracellular mechanisms triggering gonadotropin secretion”, *Rev. Reprod.*, 1(1359-6004/96), 193-202.1996.
3. Anselin, Luc. “Spatial econometrics methods and models” Dordrecht; Kluwer Academic Publishers.1988.
4. Arnold BC., and Robertson CA., Autoregressive logistic processes. *J. Appl. Prob.* 26,524-521, 1989.
5. Bahceci M., Ulug U., Ben-Shlomo I., Erden HF., Akman MA., “Use of a GnRH antagonist in controlled ovarian hyper stimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study”. *Journal of Reproductive Medicine*; 50(2):84–90, 2005.
6. Barbalat, I Systems d`equations differentile d`oscillations non lineaires, *Rev.Rourmaine Maths. Pures. Appl.*4,267-270,1959.
7. Bartrop RW., Luckhurst E., Lazarus L., Kiloh LG., and Penny R., “Depressed lymphocyte function after bereavement”. *Lancet*; 1:834, 197, 1982.

8. Beitins IZ., DufauML., O’Loughlin K., and Catt KJ,McArthur JW., “Analysis of biological and immunological activities in the two pools of LH released during constant infusion of luteinizing hormone releasing hormone (LHRH) in men”. *J Clin Endocrinol Metab* 45:605–608, 1977.
9. Bertram R., and Li Y., “A mathematical model for the actions of activin, inhibin and follistatin on pituitary gonadotrophs”, *Bull.Math.Bio.*, 70,2211-2228,2008.
10. Bhattacharyya G.K., “Parametric Models and Inference Procedures for Accelerated Life a Test”, 1987.
11. Brasileiro de Reproducao Assistida Hohmann FP., Macklon NS, Fauser BC., “A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol”. *The Journal of Clinical Endocrinology and Metabolism*; 88(1):166–73, 2003.
12. Broqua P., et al., “Pharmacological Profile of a New, Potent, and Long-Acting Gonadotropin-Releasing Hormone Antagonist: Degarelix” *J. Pharmacol. Exp. Ther.*, Vol. 301, Pp. 95-102, 2002.
13. Cannon WB., “The emergency function of adrenal medulla in pain and the major emotions,” *American Journal of Physiology*, 33: 356 -372, 1914.
14. Cannon WB. “Stresses and Strains of Homeostasis”, *American Journal of Medical Science*, 1935.

15. Cannon WB., “Bodily changes in pain, hunger, fear and rage: An account of recent research into the function of emotional excitement,” (2nd ed.), Appleton -Century–Crofts, New York, 1929.
16. Carson ER., Cobeli C., and Finkelstein L., “Mathematical modelling of metabolic and endocrine systems”, Wiley, New York, 1983.
17. Castillo RH., Matteri RL., Dumesic DA., “ Luteinizing hormone synthesis in cultured fetal human pituitary cells exposed to gonadotropin-releasing hormone” J. Clin.Endocrinol Metab 75:318–322, 1992.
18. Chandran UR., Attardi B., Friedman R., Dong K-W., Roberts JL and DeFranco DB., “Glucocorticoidreceptor-mediated repression of gonadotropin-releasing hormone promoter activity in GT1 hypothalamic cell lines”, Endocrinology 134 1467–1474, 1994.
19. Cheng CK., Leung PC., “Molecular biology of gonadotropin releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans”. Endocr Rev 26:283–306, 2005.
20. Cheng M., Chao H., and Wang P., “Medical treatment for uterine myomas”, Taiwan J. Obstet Gynecol., 47(1),18-23,2008.
21. Chrousos GP., and Gold PW., “The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis”. JAMA; 267:1244-52.36, 1992.

-
22. Churilov A., Medvedev A and Shepeljavyi A., “Mathematical Model of Non-Basal testosterone Regulation in the Male by Pulse Modulated Feedback,” *Automatica*, Vol. 45, Pp. 78-85, 2009.
 23. Clark SJ., Hauffa BP., Rodens KP., Styne DL., Kaplan SL., and Grumbach MM., “Hormone ontogeny in the ovine fetus. XIX. The effect of a potent luteinizing hormone-releasing factor agonist on gonadotropin and testosterone release in the fetus and neonate”. *Pediatr Res* 25:347–35, 1989.
 24. Conn PM., Crowley WF Jr., “Gonadotropin-releasing hormone (GnRH) and its analogs”, *Annu Rev.Med* ; 45,390-405,1994.
 25. Crow LH., “On Tracking Reliability Growth, projection from Delayed fixes”, *Proceedings Annual Reliability and Maintainability Symposium*, pp.84-89, 1983.
 26. Crow LH., et al., “Reliability Analysis for Complex, Repairable Systems, in *Reliability and Biometry*”, ed. pp.379-410, Philadelphia, SIAM, 1974.
 27. Crow LH., “On Tracking Reliability Growth *Proceedings Annual Reliability and Maintainability Symposium*”, pp. 438-443, 1975.
 28. Crow LH., “An Extended Reliability Growth Model for Managing and Assessing Corrective Actions” at the *Reliability and Maintainability Symposium*, LosAngeles, CA, http://www.reliasoft.com/pubs/2004rm06B_01.pdf 2004.

-
29. Crow LH., “Reliability Growth Planning, Analysis and Management,” 2011.
 30. David E. Mortin., and Stephen P. Yuhas., “Reliability Growth Applications and Advancements” 19 November 2001, U.S. Army Test and Evaluation Command [http://www.ndia.org/Content/Content Groups / Industrial Working Groups /Industrial Committee on Operational Test and Evaluation /PDFs22/Mortin-Yuhas.pdf](http://www.ndia.org/Content/Content%20Groups/Industrial%20Working%20Groups/Industrial%20Committee%20on%20Operational%20Test%20and%20Evaluation/PDFs22/Mortin-Yuhas.pdf) Reliability and Maintainability Symposium, January, 2011.
 31. Depalo R., Lorusso F., Palmisano M., Bassi E., Totaro I., Vacca M., et.al. “Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer”. *Gynecological Endocrinology*;25(5):328–34, 2009.
 32. Do Valle ER., Cruz LC., “GnRH enhances the caving rate of beef females administered norgestomet and alfaprostol for estrus synchronization”, *J.Anim.Sci.*75:897, 1997.
 33. Dohrenwend B.P., “The social psychological nature of stress; A frame work for causal inquiry”, *J .Abnormal Soc.Psychology*,62;294-302,1961.
 34. Duane J.T., “Learning curve Approach to Reliability Monitoring”. *IEEE Transactions on Aerospace Vol2:563-566*, 1964.
 35. Ellner PM., Broemm WJ. and Woodworth WJ. , “Reliability Growth Guide,” Technical Report 652, AMSAA. [380], 2000.

-
36. Farhy L.S., “Modelling of oscillations of endocrine networks with feedback”. *Methods in Enzymology*, 384, 54–8, 2004.
 37. Finch AR., Caunt CJ., Armstrong SP. and McArdle CA., “Agonist-Induced internalization and down regulation of gonadotropin-releasing hormone receptors”, *Am J. Physiol. Cell Physiol.*, 297(3), 591-600, 2009.
 38. Finkelstein JS., Spratt DL., O’Dea L St L., Whitcomb RW., Klibanski A., Schoenfeld DA., Crowley Jr WF “Pulsatile gonadotropin secretion after discontinuation of long term gonadotropin-releasing hormone (GnRH) administration in a subset of GnRH-deficient men”. *J Clin Endocrinol Metab* 69:377–385, 1989.
 39. Firouzabadi RD., Ahmadi S., Oskouian H., Davar R., “Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. *Archives of Gynecology and Obstetrics*; 281(1):81–5, 2010.
 40. Franco Pellerrey., “Partial orderings under cumulative damage shock models”, *Advances in Applied Probability*, 25(4): 939-946, 1993.
 41. Franco Jr JG., Baruffi RLR., Petersen CG., Mauri AL., Felipe V., Contart P., “Comparison of ovarian stimulation with recombinant FSH After 2nd phase protocols with GnRH Analogs (I-estradiol +ganirelix versus II-nafarelin) [Comparacao da estimulacao ovariana com FSH recombinante apos protocolo de 2A fase com analogos do GnRH (I –estradiol + ganirelix versus II–nafarelin)]. *Jornal* 2007.

-
42. Frankenhaeuser M., “ Sympathetic adreno-medullary activity, behavior and the Psychosocial environment”, In. Venables PH and Chirstle MJ Eds., Research in Psychophysiology, New York, London and Sydney, John Wiley and Sons, 71-97, 1975
 43. Frankenhaeuser M., “A psychobiological framework for research on human Stress and coping. In Appley HH and Trumbull R (Eds.), Dynamics of Stress: Physiological, Psychological and Social Perspective,” Plenum press, New York, 101–116, 1986.
 44. Frankenhaeuser M., “Experimental approaches to the study of catecholamines and emotion”, Emotions-Their parameters and Measurements edited by Levi L., Raven Press, New York, 209-234, 1975.
 45. Franklin DK., Porsolt S., Bonsignori A., Carfagna N., and McArthur RA., 2000, Reboxetine: “A Pharmacologically Potent, Selective, and Specific Norepinephrine uptake Inhibitor, Biol. Psychiatry, 47, 818-829, 1993.
 46. Griffin JE., et al., “Williams Textbook of Endocrinology”, Philadelphia, W. B. Saunders Co., p 259. 1985.
 47. Grossman Z., Polis M., Feinberg M I., Levi S., Jankelevich R., Yarchoan J., Boon F., de Wolf J., Lange J., Goudsmit D., Dimitrov W. Paul., “ Ongoing HIV dissemination during HAART”, Nat. Med. 5 1099, 1999.
 48. Hans Selye., “Selye’s Guide to Stress Research”, Van Nostrand Reinhold Company, Newyork, 1980.

-
49. Hoare SR., Sullivan SK., Ling N., Crowe PD., and Grigoriadis DE., “Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists”, *Mol Pharmacol*, 63(3) 751–765, 2003.
 50. Horstmann S and Binder EB., “Glucocorticoids as predictors of treatment response in depression”. *Harv Rev Psychiatry*; 19:125-43, 2011.
 51. Huirne JAF., “Gonadotropin-releasing hormone receptor antagonists”, *Lancet*, 358, 1793-1803, 2001.
 52. Ji Hwan Chaa., Etui Yong Lee ba., “An extended stochastic failure model for a system subject to random shocks”. Republic of Korea. Seoul, 120-750, 2010.
 53. Johansson G., “Activation, adjustment and Sympathetic adrenal medullary activity, Field of laboratory studies of adults and children”. Reports from the Psychological Laboratories, University of Stockholm, Suppl.21, 1973.
 54. John S. Usher “Case Study: Reliability Models and Misconceptions”, *Quality Engineering*, Volume 6, Issue 2, pp 261- 271, 1993.
 55. Johnson NL. and Kotz., S. “Distributions in Statistics: Continuous Univariate Distribution”, Vol. II. Wiley, New York, 1970.
 56. Jungwirth A., et al., “Inhibition of Growth of Androgen-Independent DU-145 Prostate Cancer in Vivo by Luteinising Hormone-Releasing Hormone Antagonist Cetrorelix and Bombesin Antagonists RC-3940-II and RC-3950-II”, *Eur. J. Cancer*, Vol. 33, Pp. 1141-1148, 1997.

-
57. Karsch FJ., Bowen JM., Caraty A., Evans NP., and Moenter SM., Gonadotropin-releasing hormone requirements for ovulation. *Biol Reprod* 56:303–30, 1997.
 58. Kdous M., Chaker A., Bouyahia M., Zhioua F., Zhioua A., “Increased risk of early pregnancy loss and lower live birth rate with GnRH antagonists vs. long GnRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation”. *La Tunisie Medicale*; 87(12):834–42, 2009.
 59. Keenan DM., et al., A feedback-controlled ensemble model of the stress-responsive hypothalamo pituitary adrenal axis *Soc.Ind. Appl. Math .J. Appl. Math* 61:934–965, 2000.
 60. Keenan DM., Veldhuis JD., “A biomathematical model of time-delayed feedback in the human male hypothalamic-pituitary-Leydig cell axis. *Am. J. Physiol*”, *Endocrinol. Metab.* 275 (1), E157–E176, 1998.
 61. Keller-Wood M. E. & Yates, F. E. *Endocr. Rev.* 5, 1–24, 1984.
 62. Kesler D.J., Troxel T.R, Hixon D.L., “Effect of the days postpartum and exogenous GnRH on reproductive hormone and Ovarian changes in postpartum suckled beef cows”, *Heriogenology* 13:287, 1980.
 63. Kim SH., Hu Y., Cadman S., Bouloux P., “Diversity in fibroblast growth factor receptor 1 regulation: Learning from the investigation of Kallmann syndrome”, *J Neuroendocrinol* 20:141–163, 2008.
 64. Kolibianakis EM., Collins J., Tarlatzis BC., Devroey P., Diedrich K., Griesinger G., “Among patients treated for IVF with gonadotropins and

- GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis”, *Human Reproduction Update*; 12(6):651–71, 2006.
65. Kuang Y., “Delay Differential Equations with Applications in Population Dynamics”, Academic Press, Boston, 1993.
66. Laakmann G., [Psychopharmaco-Endocrinology and Depression Research], Monogra Gesamtgeb, Penttila J., Syvalahti E., Hinkka S., Kuusela T., and Scheinin H., 2001. “The Effects of Amitriptyline, Citalopram and Reboxetine on Autonomic Nervous System, A Randomized Placebo-Controlled Study on Healthy Volunteers”, *Psychopharmacology (Berl.)*, 154, 343-349, 2001.
67. Laakmann G., Wittmann M., Schoen H. W., Zygan K., Weiss A., Meissner R., Mueller O.A., Stalla G. K., Effects of Receptor Blockers (Methysergide, Propranolol, Phentolamine, Yohimbine and Prazosin) on Desimipramine-Induced Pituitary Hormone Stimulation in Humans –III. Hypothalamic-Pituitary-Adrenocortical Axis, *Psychoneuroendocrinology*, 11, 475-489, 1986.
68. Labrie F., et al., “Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer”, *Endocr, Rev.*, Vol. 26, Pp. 361-379, 2005.
69. Lakshmi S., “A stochastic model for the time to get stress related Disease/Dysfunction by two sources”, *International Journal of Management and Systems*, 17(1): 101-115, 2001.

-
70. Lakshmi S., and Anusiya “A mathematical model for a feedback of stress responsive hormones cortisol feeds back on hypothalamic in HPA axis due to human stress”, *American Journal of Mathematics and Mathematical Sciences* Volume 2, No. 1, P13–18, 2013.
 71. Lakshmi S., and Ganesan MS., “A mathematical model in physiological behavioral science”, *Journal of Indian Academy of Mathematics*, 23, 2001.
 72. Lakshmi S., and Geetha T., “An application to stochastic clearing system”, *Journal of Indian Academy of Mathematics*, 29(1): 79-86, 2007.
 73. Lakshmi S., and Pamela S., “Tail behavior of the random products of independent regularly varying random variable glucocorticoids”, *International Journal Open Problems Computational Mathematics*, 4(3): 193-198, 2011.
 74. Lakshmi S., and Senthilkumar P., “Stochastic model for cortisol secretion due to human stress”, *Journal of Indian Academy of Mathematics*, 29(2): 313-321, 2007.
 75. Lakshmi S., and Venkatesh A., “A cumulative damage threshold crossing model for the effect of stress on dopamine levels in the cortical areas”, *Bioscience Research Bulletin*, 25 (1), 2009.
 76. Lakshmi S., and Venkatesh A., “A total down time distribution model for the release of dopamine induced by methamphetamine”, *Acta Ciencia Indica*, 2009.

-
77. Lakshmi S., "Stochastic Model for Stress Effects of Homeostatic Systems", the Journal of the Indian Academy of Mathematics, 26(2), 2004.
 78. Lakshmi S., and Karthik R., "Mathematical Model for the secretion of GnRH in beef cows by using extended Reliability growth model", Bio-Science Research Bulletin. Vol.27 (No.1) P1-5, 2011.
 79. Lakshmi S., and Ganesan MS., "A Stochastic Model in the study of cumulative effects of Human stress, Proceedings of the National Seminar on Applications of Mathematics", at St. Joseph College,137-146, 2000.
 80. Langner TS., and Michael ST., "Life Stress and Mental Health", New York, Free Press of Glence, 1963.
 81. Lazarus RS., and Launier R., "Stress related transactions between person and Environment", In Pervin L.A and Lewis M(eds),Perspectives in international Psychology, New York,pp.287-327,1978.
 82. Lazarus RS., "A cross cultural study of stress reaction", Journal of Personality and Social Psychology, 4, 622-633, 1966.
 83. Lazarus RS., and Cohen JB., "Environmental stress, in: I. Altman and J.F Wohlwill Eds, Human behavior and the environment", Current theory and Research, New York, Plenum, 2: 89-127, 1977.
 84. Lazarus RS., and Folkman S., "Stress, appraisal and coping", Springer, New York, 1984.
 85. Lee JR., Kim SH., Kim SM., Jee BC., Ku SY., Suh CS., et al. "Follicular fluid antiüllerian hormone and inhibin B concentrations: comparison

-
- between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles”. *Fertility and Sterility*; 89(4):860–7,2008.
86. Lewls PAW., “Some simple models for continuous variate time series”. *Water Resources Bull.* 21, 625-644, 1985.
87. Liezmann C., Klapp B., Peters EM., “Stress, atopy and allergy: A re-evaluation from a psychoneuro immunologic perspective”, *Dermatoendocrinol* 3:37-40, 2011.
88. Loriaux L., and Nieman L., “Stress and reproduction: the role of cortisol”, in *Neuroendocrine Regulation of Reproduction* pp 307–311, 1990.
89. Lu ZL., “Signaling diversity and ligand-induced selectivity at the human GnRH receptor”, in *The Endocrine Society’s 92 Annual Meeting*, San Diego, 19-22,2010.
90. Mason WJ., “A Historical view of the stress field”, *Journal of Human Stress*, I (3), 22-26, 1975.
91. Mason WJ., “A Historical view of the stress field”, *Journal of Human Stress*, I (2), 22-36, 1975.
92. McCann SM., and Yu WH., “FSH-releasing peptides. US Patent 6,200,471. Padmanabhan, V., F. J. Karsch, and J. S. Lee. 2002. Hypothalamic, pituitary and gonadal regulation of FSH. *Reproduction* (Cambridge, England) Supplement 59: 67-82, 2001.

-
93. Millar RP., “Gonadotropin-releasing hormone (GnRH)’s and GnRH receptors”, *Anim Reprod Sci* 88:5–28, 2005.
 94. Murray JD., *Mathematical Biology, I: An Introduction*, 3rd ed. Springer, New York, 2002.
 95. Naor Z., “Signal transduction mechanisms of Ca^{2+} -mobilizing hormones: the case of gonadotropin-releasing hormone”, *Endocr Rev.*, 11(2), 326, 1990.
 96. Neill JD., “Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism”, *Nat Genet* 18:14–15, 1998.
 97. Nelson P., Mittler J. Perelson., “An Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV-1 viral dynamic parameters”, *J. AIDS* 26 405, 2001.
 98. Ngan ES., Cheng PK., Leung PC., Chow BK., “Steroidogenic factor-1 interacts with a gonadotrope specific element within the first exon of the human gonadotropin-releasing hormone receptor gene to mediate gonadotrope-specific expression”, *Endocrinology* 140:2452–2462, 1999.
 99. NIST/SEMATECH e-Handbook of Statistical Methods, Chapter 8.1.9 “How can you model reliability growth?” [http:// www.itl.nist.gov /div898 /handbook /apr /section1 /apr19.htm](http://www.itl.nist.gov/div898/handbook/apr/section1/apr19.htm), 2010.
 100. Oppenheim DS., Bikal H., Crowle WF., “Effects of chronic GnRH analogue administration on gonadotropin and α -subunit secretion in post-menopausal women”, *Clin .Endocrinol(oxf)* 39,559-564,1992.

-
101. Orvieto R., Meltzer S., Rabinson J., “GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity”, *Fertility and Sterility*; 90(4):1294–6, 2008.
 102. Pabuccu R., Onalan G., Selam B., Ceyhan T., Akar M., Onalan R., “Comparison of GnRH agonist and antagonist protocols among patients with mild-moderate endometriosis and endometrioma: A novel clinical approach. *Fertility and Sterility*”; 84 Suppl 1: 197–8, 2005.
 103. Padmanabhan, V., Karsch FJ., and Lee JS., “Hypothalamic, pituitary and gonadal regulation of FSH”, *Reproduction (Cambridge, England) Supplement* 59: 67-82, 2002.
 104. Phillips DJ., and Clarke IJ., “Effects of the synthetic glucocorticoid dexamethasone on reproductive function in the ewe”, *Journal of Endocrinology* 126 289–295, 1990.
 105. Popa SM., Clifton DK., and Steiner RA., “The role of kisspeptins and GPR54 in the neuroendocrine regulation of reproduction”. *Annu Rev Physiol* 70:213–238, 2008.
 106. Porter JF., Editor, “The Control of Human Fertility Status”, (Second Edition), 39-50, Blackwell Scientific Publication, Oxford, London, (1987).
 107. Quintero L., Cardenas R., Suarez-Roca H., “Stress-induced hyperalgesia is associated with a reduced and delayed GABA inhibitory control that

-
- enhances post-synaptic NMDA receptor activation in the spinal cord”,
Pain; 152:1909-22, 2011.
108. Rao PS., and Johnson DH., “A first-order A R model for non-Gaussian time series”, Proc. IEEE Int. Conf. on ASSP. 2, 1524-1527, 1988.
109. Reame NE., Sauder SE., Case GD., Kelch RP., Marshall JC 1985 “Pulsatile gonadotropin secretion in women with hypothalamic amenorrhea: evidence that reduced frequency of gonadotropin-releasing hormone secretion is the mechanism of persistent anovulation”, J Clin Endocrinol Metab 61:851–858, 1985.
110. Reinhart GJ., Xie Q., Liu XJ., Zhu YF., Fan J., Chen C., et al., “Species selectivity of non-peptide antagonists of the gonadotropin-releasing hormone receptor is determined by residues in extracellular loops II and III and the aminoterminal”, J.Biol. Chem., 279(33), 34115–22, 2004.
111. Reliability Growth-Statistical test and estimation methods, IEC International Standard IEC61164. International Electro technical commission, 1995.
112. Richard Lazarus., “Psychological Stress and the coping process”, McGraw Hill, New York.1966.
113. Rivier J., porker J., et al., The gonadotropin-releasing hormone antagonists with N omegatriazolylornithinc,-lysine,or-p-aminophenylalanine residues positions 5and 6 J Med Chem,35,4270-278,1992.

-
114. Ross G. T., et al. "Williams Textbook of Endocrinology", Philadelphia, W. B. Saunders Co., p. 206, 1985.
115. Rouche J.R., "Fertility in cows after treatment with a prostaglandin analogue with or without progesterone", *J.Reprod.Fert*; 46:341, 1976.
116. Saketos M., Sharma N., and Santoro NF., "Suppression of the hypothalamic-pituitary-ovarian axis in normal women by glucocorticoids", *Biology of Reproduction* 49 1270-1276, 1993.
117. Schiavo M., Lo B., Prinari B.C., Seriode A.V., "Mathematical modelling of quality in a medical structure: A case study", *Applicate per l'Ingegneria Roma, Italy* March 14, 2011.
118. Selye H., "Stress in Health and disease", Reading, Massachusetts, Butterworths, 1976.
119. Selye H., "Stress without distress", New York: JB. Lippincot, 1974.
120. Selye H., "The Stress of Life", McGraw Hills, New York: 1976.
121. Selye H., "The Physiology and Pathology of Exposure to stress" montreal, Acta, Inc., 1950.
122. Seminara SB., Hayes FJ. Crowley WF. Jr., "Gonadotropin-releasing hormone deficiency in the human; Pathophysiological and Genetic considerations", *Endocr.Rev*; 19(5)521-39, 1998.
123. Shanthikumar JG., and Sumitha U., "A Class of Correlated Cumulative Shock Models", *Advances in Applied Probability*, 17:347-366, 1985.

-
124. Shanthikumar JG., and Sumitha U., “Distribution properties of the system failure time in a general Shock Model”, *Advances in Applied Probability*, 16: 363-377, 1984.
 125. Shanthikumar JG., and Sumitha U., “General Shock Models Associated with Correlated Renewal Sequences”, *Advances in Applied Probability*, 20: 600-614, 1983.
 126. Showe B., et al. J. Human Luteinizing Hormone, Follicle stimulating hormone *Clin. Endocrinol. Metab.* 39:187,1974.
 127. Smith WR., “Hypothalamic Regulation of Pituitary Secretion of Luteinising Hormones-II Feedback Control of Gonadotropin Secretion”, *Bull. Math. Biol.*, 42, 57-58, 1980.
 128. Smulders B., van Oirschot SM., Farquhar C., Rombauts L., Kremer JAM., “Oral contraceptive pill, progestogen or estrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques”, *Cochrane Database of Systematic Reviews*, Issue 1. [DOI: 10.1002/14651858] 2010.
 129. Stoebel DP., and Moberg GP., “Repeated acute stress during the follicular phase and luteinizing hormone surge of dairy heifers *Journal of Dairy Science*”, 65, 92–96, 1982.
 130. *The Gale Encyclopedia of Science*. Ed. Bridget Taverns. Vol. 3. Detroit, ML Gale Research, an International Thomson Company, 1996.

-
131. Tobet SA., and Schwarting GA., “Recent progress in gonadotropin releasing hormone neuronal migration”, *Endocrinology* 147:1159–1165, 2006.
132. Tomera K., Gleason D., Gittelman M., Moseley W., Zinner N., and Murdoch M., et al., “The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer”, *J Urol.*, 165(5)1585–9, 2001.
133. Tornoe CW., et al., “Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modelling of the Hypothalamic-Pituitary Gonadal Axis Following Treatment with GnRH Analogues”, *Br. J. Clin. Pharmacol.*, Vol. 63, Pp. 648-664, 2007.
134. Turner AI., Hemsworth PH., Hughes PE., and Tilbrook AJ., “Repeated acute activation of the hypothalamo pituitary adrenal axis prior to and during estrus did not affect reproductive performance in gilts *Biology of Reproduction*”, 58 1458–1462, 1998b.
135. Turner AI., Hemsworth PH., Hughes PE., Canny BJ., and Tilbrook AJ., “The effect of repeated boar exposure on cortisol secretion and reproduction in gilts *Animal Reproduction Science*”, 51 143–154, 1998a.
136. Uma s., and Lakshmi., “Stochastic Model for Predicting Decreased Hythalamus, Pituitary Adenal Axis and Autonomic Activity During

-
- Stress in Delinquent Male Adolescents and controls”, *The Journal of the Indian Academy of Mathematics*, 32(2), 2010.
137. Van Poppel H., et al., “Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker– Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer”, *Eur. Urol.*, Vol. 54, Pp. 805-815, 2008.
138. Vlaisavljevic V., Reljic M., Lovrec VG., Kovacic B., “Comparable effectiveness using flexible single-dose GnRH antagonist (cetorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study”, *Reproductive Biomedicine Online*; 7(3):301–8, 2003.
139. White RB., Eisen JA., Kasten TC., Fernald RD., “Second gene for Gonadotropin-releasing hormone in human *Proc .Nat L. Acad .Sci USA* 95 05-309, 1998.
140. Willman SP., and Kliman HJ., “Comparison of the luteal phase after pituitary suppression with GnRH-agonist versus GnRH antagonist in controlled ovarian stimulation”. *Fertility and Sterility*; 84 Suppl: 308, 2005.
141. Wong EHF., Sonders MS., Amara SG., Tinholt PM., Piercy MFP., Hoffmann WP., Hyslop B. Zwillinger., “*Handbook of Differential Equations*,” Acedemic, 1992.
142. Yeh HC., Arnold BC., and Robertson CA., Pareto processes. *J. Appl. Prob.* 25, 291-201. 521,1988.

-
143. Yeh., Huang G., Zeng P., Pei L., “IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study”. *Journal of Assisted Reproduction and Genetics*; 2(3):105–11, 2009.
144. Yu WH., Karanth S., Mastronardi CA., Sealfon S., Dean C., DeesWL., and McCann SM., “Lamprey GnRH-III acts on its putative receptor via nitric oxide to release follicle stimulating hormone specifically”, *Experimental Biology and Medicine* Maywood, N.J 227: 786-792, 2002.
145. Zhu YF., Chen C., Struthers RS., “Nonpeptide gonadotropin releasing hormone antagonists”, *Ann. Rep. Med. Chem.*, 39(82004), 99–110, 2004.
146. Zikopoulos K., Kaponis A., Adonakis G., Sotiriadis A., Kalantaridou S., Georgiou I., et al., “A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia”, 83(5):1354-62, 2005.
147. Zinner NR. et al., “Similar Frequency of Testosterone Surge After Repeat Injections of Goserelin (Zoladex) 3.6 mg and 10.8 mg: Results of a Randomized Open-Label Trial”, *Urology*, Vol. 64, Pp. 1177-1181, 2004.